68Ga/ 177lu标记的fap靶向肽用于肿瘤放射药物成像和治疗的临床前评价

Rang Wang, Mingxing Huang, Weichen Wang, Mufeng Li, Yingwei Wang, Rong Tian
{"title":"68Ga/ 177lu标记的fap靶向肽用于肿瘤放射药物成像和治疗的临床前评价","authors":"Rang Wang, Mingxing Huang, Weichen Wang, Mufeng Li, Yingwei Wang, Rong Tian","doi":"10.2967/jnumed.124.268689","DOIUrl":null,"url":null,"abstract":"<p>Fibroblast activation protein (FAP) has been considered a promising target for tumor imaging and therapy. This study designed a novel peptide, FAP-HXN, specifically targeting FAP and exhibiting significant potential as a radionuclide-labeled theranostic agent. Preclinical studies were conducted to evaluate the potency, selectivity, and efficacy of FAP-HXN. <strong>Methods:</strong> FAP-HXN was synthesized and characterized for selectivity and specificity toward FAP. Cellular uptake of the radiolabeled FAP-HXN in human embryonic kidney (HEK)-293-FAP cells with high expressions of FAP was evaluated. The diagnostic and therapeutic potential of <sup>68</sup>Ga- and <sup>177</sup>Lu-labeled radioligands was evaluated in HEK-293-FAP tumor-bearing mice compared with the FAP-targeting peptide FAP-2286. <strong>Results:</strong> FAP-HXN demonstrated high binding ability to human and mouse sources of FAP. Moreover, the in vivo studies confirmed the high affinity and specificity of radiolabeled FAP-HXN. Small-animal PET imaging demonstrated that [<sup>68</sup>Ga]Ga-FAP-HXN had continuous tumor uptake in FAP-positive tumors after administration compared with [<sup>68</sup>Ga]Ga-FAP-2286. In the therapeutic experiments, [<sup>177</sup>Lu]Lu-FAP-HXN showed significant antitumor activity in HEK-293-FAP xenografts at well-tolerated doses, which also exhibited longer tumor retention and better tumor growth inhibition compared with [<sup>177</sup>Lu]Lu-FAP-2286. <strong>Conclusion:</strong> The preclinical studies revealed that radiolabeled FAP-HXN had high tumor uptake, prolonged retention, and significant anticancer efficacy in HEK-293-FAP xenografts. FAP-HXN shows promising potential as a novel theranostic radioligand for FAP-positive tumors.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preclinical Evaluation of 68Ga/177Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy\",\"authors\":\"Rang Wang, Mingxing Huang, Weichen Wang, Mufeng Li, Yingwei Wang, Rong Tian\",\"doi\":\"10.2967/jnumed.124.268689\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Fibroblast activation protein (FAP) has been considered a promising target for tumor imaging and therapy. This study designed a novel peptide, FAP-HXN, specifically targeting FAP and exhibiting significant potential as a radionuclide-labeled theranostic agent. Preclinical studies were conducted to evaluate the potency, selectivity, and efficacy of FAP-HXN. <strong>Methods:</strong> FAP-HXN was synthesized and characterized for selectivity and specificity toward FAP. Cellular uptake of the radiolabeled FAP-HXN in human embryonic kidney (HEK)-293-FAP cells with high expressions of FAP was evaluated. The diagnostic and therapeutic potential of <sup>68</sup>Ga- and <sup>177</sup>Lu-labeled radioligands was evaluated in HEK-293-FAP tumor-bearing mice compared with the FAP-targeting peptide FAP-2286. <strong>Results:</strong> FAP-HXN demonstrated high binding ability to human and mouse sources of FAP. Moreover, the in vivo studies confirmed the high affinity and specificity of radiolabeled FAP-HXN. Small-animal PET imaging demonstrated that [<sup>68</sup>Ga]Ga-FAP-HXN had continuous tumor uptake in FAP-positive tumors after administration compared with [<sup>68</sup>Ga]Ga-FAP-2286. In the therapeutic experiments, [<sup>177</sup>Lu]Lu-FAP-HXN showed significant antitumor activity in HEK-293-FAP xenografts at well-tolerated doses, which also exhibited longer tumor retention and better tumor growth inhibition compared with [<sup>177</sup>Lu]Lu-FAP-2286. <strong>Conclusion:</strong> The preclinical studies revealed that radiolabeled FAP-HXN had high tumor uptake, prolonged retention, and significant anticancer efficacy in HEK-293-FAP xenografts. FAP-HXN shows promising potential as a novel theranostic radioligand for FAP-positive tumors.</p>\",\"PeriodicalId\":22820,\"journal\":{\"name\":\"The Journal of Nuclear Medicine\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Nuclear Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2967/jnumed.124.268689\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.124.268689","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

成纤维细胞活化蛋白(FAP)被认为是肿瘤成像和治疗的一个有前景的靶点。本研究设计了一种新的肽,FAP- hxn,专门针对FAP,并显示出作为放射性核素标记治疗剂的巨大潜力。临床前研究评估了FAP-HXN的效价、选择性和疗效。方法:合成FAP- hxn,并对其进行选择性和特异性表征。研究了放射性标记的FAP- hxn在高表达的人胚胎肾(HEK)-293-FAP细胞中的细胞摄取情况。在HEK-293-FAP荷瘤小鼠中比较68Ga-和177lu标记放射配体与fap靶向肽FAP-2286的诊断和治疗潜力。结果:FAP- hxn对人和小鼠的FAP源具有很强的结合能力。此外,体内研究证实了放射性标记FAP-HXN的高亲和力和特异性。小动物PET成像显示,与[68Ga]Ga-FAP-2286相比,[68Ga]Ga-FAP-HXN在给药后对fap阳性肿瘤持续摄取。在治疗实验中,与[177Lu]Lu-FAP-2286相比,[177Lu]Lu-FAP-HXN在耐受良好的剂量下对HEK-293-FAP异种移植物显示出显著的抗肿瘤活性,并且具有更长的肿瘤保留时间和更好的肿瘤生长抑制作用。结论:临床前研究表明,放射性标记的FAP-HXN在HEK-293-FAP异种移植物中具有较高的肿瘤摄取、较长的滞留时间和显著的抗癌效果。FAP-HXN作为一种新的治疗fap阳性肿瘤的放射配体显示出很大的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Preclinical Evaluation of 68Ga/177Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy

Fibroblast activation protein (FAP) has been considered a promising target for tumor imaging and therapy. This study designed a novel peptide, FAP-HXN, specifically targeting FAP and exhibiting significant potential as a radionuclide-labeled theranostic agent. Preclinical studies were conducted to evaluate the potency, selectivity, and efficacy of FAP-HXN. Methods: FAP-HXN was synthesized and characterized for selectivity and specificity toward FAP. Cellular uptake of the radiolabeled FAP-HXN in human embryonic kidney (HEK)-293-FAP cells with high expressions of FAP was evaluated. The diagnostic and therapeutic potential of 68Ga- and 177Lu-labeled radioligands was evaluated in HEK-293-FAP tumor-bearing mice compared with the FAP-targeting peptide FAP-2286. Results: FAP-HXN demonstrated high binding ability to human and mouse sources of FAP. Moreover, the in vivo studies confirmed the high affinity and specificity of radiolabeled FAP-HXN. Small-animal PET imaging demonstrated that [68Ga]Ga-FAP-HXN had continuous tumor uptake in FAP-positive tumors after administration compared with [68Ga]Ga-FAP-2286. In the therapeutic experiments, [177Lu]Lu-FAP-HXN showed significant antitumor activity in HEK-293-FAP xenografts at well-tolerated doses, which also exhibited longer tumor retention and better tumor growth inhibition compared with [177Lu]Lu-FAP-2286. Conclusion: The preclinical studies revealed that radiolabeled FAP-HXN had high tumor uptake, prolonged retention, and significant anticancer efficacy in HEK-293-FAP xenografts. FAP-HXN shows promising potential as a novel theranostic radioligand for FAP-positive tumors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信